摘要:
Die Erfindung betrifft die Verwendung von Sulfonamid-Derivaten der allgemeinen Formel worin
R nieder-Alkyl, Phenyl, Benzyl, Naphthyl, Pyridyl oder Thienyl, gegebenenfalls einfach oder mehrfach substituiert durch nieder-Alkyl, nieder-Alkoxy, nieder-Alkyl-carbonyl-amino, Halogen, Cycloalkyl, Nitro, Amino, Methylendioxy, Phenoxy oder Benzyloxy, wobei die aromatischen Ringe wiederum durch Nitro, Halogen oder Amino substituiert sein können, R 1 -R 4 Wasserstoff, Halogen, Hydroxy, nieder-Alkyl, Nitro, Cyano, Amino, nieder-Alkoxy, Benzyloxy, Trifluormethyl oder Phenyl, gegebenenfalls einfach oder mehrfach substituiert durch nieder-Alkyl, Trifluormethyl, Nitro, Amino oder Hydroxy, und wobei R 1 und R 2 oder R 2 und R 3 zusammen einen Benzolring bilden können, der gegebenenfalls substituiert sein kann durch Halogen, Trifluormethyl, Nitro, nieder-Alkyl oder nieder-Alkoxy, bedeuten, sowie von deren pharmazeutisch annehmbare Salze als Kynurenin-3-Hydroxylase Hemmstoffe bei der Bekämpfung oder Verhütung von neurodegenerativen Erkrankungen, neurologischen Erkrankungen als Folge einer Aktivierung des Immunsystems, von psychiatrischen Leiden bzw. zur Herstellung entsprechender Arzneimittel.
摘要:
The present invention provides the use of compounds of general formula I and compounds of general formula II as modulators and affinity labels of the MPTP complex. Furthermore, the present invention provides methods for modulating the activity of the MPTP complex, methods for determining the presence of a component of the MPTP complex, and methods for identifying an active agent that modulates the activity of the MPTP complex, specifically methods for identifying an active agent that modulates the activity of the MPTP complex by interacting with the VDAC1 component. Moreover, novel compounds of general formula I are provided by the present invention.
摘要:
The present invention relates to compounds of the general formula wherein R 1 is C 6 - 10 -cycloalkyl, optionally substituted by lower alkyl or -C(O)O-lower alkyl; decahydro-naphthalen-1-yl; decahydro-naphthalen-2-yl; indan-1-yl or indan-2-yl, optionally substituted by lower alkyl; decahydro-azulen-2-yl; bicyclo[6.2.0]dec-9-yl; acenaphthen-1-yl; 2,3-dihydro-1H-phenalen-1-yl; 2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl or octahydro-inden-2-yl; R 2 is hydrogen; lower alkyl; =O or phenyl, optionally substituted by lower alkyl, halogen or alkoxy; A○ is cyclohexyl or phenyl, optionally substituted by lower alkyl, halogen or alkoxy; X is -CH(OH)-; -C(O)-; -CHR 3 -; -CR 3 =; -O-; -S-; -CH(COOR 4 )- or - C(COOR 4 )=; Y is -CH 2 -; -CH=; -CH(COOR 4 )-, -C(COOR 4 )=; or -C(CN)-; R 3 is hydrogen or lower alkoxy; R 4 is lower alkyl, cycloalkyl, phenyl, or benzyl and either a or b is optionally an additional bond, and to pharmaceutically acceptable acid addition salts thereof. The compounds are agonists and/or antagonists of the orphanin FQ (QFQ) receptor and therefore useful in the treatment of diseases, related to this receptor.
摘要:
The present invention relates to compounds of the general formula wherein
R 1 is hydrogen, lower alkyl, halogen, lower alkoxy, trifluoromethyl, lower alkyl-phenyl or (C 5 - 7 )-cycloalkyl; R 2 is hydrogen, lower alkyl, phenyl or lower alkyl-phenyl; R 3 is hydrogen, lower alkyl, benzyl, lower alkyl-phenyl, lower alkyl-diphenyl, triazinyl, cyanomethyl, lower alkyl-piperidinyl, lower alkyl-naphthyl, (C 5 - 7 )-cycloalkyl, lower alkyl-(C 5 - 7 )-cycloalkyl, lower alkyl-pyridinyl, lower alkyl-morpholinyl, lower alkyl-dioxolanyl, lower alkyl-oxazolyl or lower alkyl-2-oxo-oxazolidinyl and wherein the ring systems may be substituted by additional lower alkyl, lower alkoxy, trifluoromethyl or phenyl, or -(CH 2 ) n C(O)O-lower alkyl, -(CH 2 ) n C(O)NH 2 , -(CH 2 ) n C(O)N(lower alkyl) 2 , -(CH 2 ) n OH or -(CH 2 ) n C(O)NHCH 2 C 6 H 5 ; R 4 is hydrogen, lower alkyl or nitrilo; A is a ring system, consisting of
(a) (C 5 - 15 )-cycloalkyl, which may be in addition to R 4 optionally substituted by lower alkyl, trifluoromethyl, phenyl, (C 5 - 7 )-cycloalkyl, spiro-undecan-alkyl or by 2-norbornyl, or is one of the following groups dodecahydro-acenaphthylen-1yl (e), bicyclo[6.2.0]dec-9-yl (f) and bicyclononan-9-yl (g);
and wherein
R 5 and R 6 are hydrogen, lower alkyl or taken together and with the carbon atoms to which they are attached form a phenyl ring; R 7 is hydrogen or lower alkyl; the dotted line represents an optional bond and
n is 1 to 4; and to pharmaceutically acceptable acid addition salts thereof. Compounds of the present invention are agonists and/or antagonists of the Orphanin FQ (OFQ) receptor. Consequently they will be useful in the treatment of memory and attention deficits, psychiatric, neurological and physiological disorders, especially, but not limited to, amelioration of symptoms of anxiety and stress disorders, depression, trauma, memory loss due to Alzheimer's disease or other dementias, epilepsy and convulsions, acute and/or chronic pain conditions, symptoms of addictive drug withdrawal, control of water balance, Na + excretion, arterial blood pressure disorders and metabolic disorders such as obesity.
摘要:
Die Erfindung betrifft die Verwendung von Sulfonamid-Derivaten der allgemeinen Formel worin R nieder-Alkyl, Phenyl, Benzyl, Naphthyl, Pyridyl oder Thienyl, gegebenenfalls einfach oder mehrfach substituiert durch nieder-Alkyl, nieder-Alkoxy, nieder-Alkyl-carbonyl-amino, Halogen, Cycloalkyl, Nitro, Amino, Methylendioxy, Phenoxy oder Benzyloxy, wobei die aromatischen Ringe wiederum durch Nitro, Halogen oder Amino substituiert sein können, R 1 -R 4 Wasserstoff, Halogen, Hydroxy, nieder-Alkyl, Nitro, Cyano, Amino, nieder-Alkoxy, Benzyloxy, Trifluormethyl oder Phenyl, gegebenenfalls einfach oder mehrfach substituiert durch nieder-Alkyl, Trifluormethyl, Nitro, Amino oder Hydroxy, und wobei R 1 und R 2 oder R 2 und R 3 zusammen einen Benzolring bilden können, der gegebenenfalls substituiert sein kann durch Halogen, Trifluormethyl, Nitro, nieder-Alkyl oder nieder-Alkoxy, bedeuten, sowie von deren pharmazeutisch annehmbare Salze als Kynurenin-3-Hydroxylase Hemmstoffe bei der Bekämpfung oder Verhütung von neurodegenerativen Erkrankungen, neurologischen Erkrankungen als Folge einer Aktivierung des Immunsystems, von psychiatrischen Leiden bzw. zur Herstellung entsprechender Arzneimittel.
摘要:
The invention relates to compounds of the general formula wherein
R 1 is C 6-12 -cycloalkyl, optionally substituted by lower alkyl or C(O)O lower alkyl, indan-1-yl or indan-2-yl, optionally substituted by lower alkyl; acenaphthen-1-yl; bicyclo[3.3.1]non-9-yl, octahydro-inden-2-yl; 2,3-dihydro-1H-phenalen-1-yl; 2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl, decahydro-azulen-2-yl; bicyclo[6.2.0]dec-9-yl; decahydro-naphthalen-1-yl, decahydro-naphthalen-2-yl; tetrahydro-naphthalen-1-yl, tetrahydro-naphthalen-2-yl or 2-oxo-1,2-diphenyl-ethyl; R 2 is =O or hydrogen, R 3 is hydrogen, isoindolyl-1,3-dione, lower alkoxy, lower alkyl, amino, benzyloxy, -CH 2 OR 5 or -CH 2 N(R 5 ) 2; R 4 is hydrogen or -CH 2 OR 5 ; R 5 is hydrogen or lower alkyl; Ⓐ is cyclohexyl or phenyl, optionally substituted by lower alkyl, halogen or alkoxy; to racemic mixtures and their corresponding enantiomers and or pharmaceutically acceptable acid addition salts thereof.
The compounds of the present invention are agonists and/or antagonists of the orphamin FQ (OFQ) receptor and therefore useful in the treatment of diseases, related to this receptor.
摘要翻译:本发明涉及通式为CHEM的化合物,其中R 1为C 6-12 - 环烷基,任选被低级烷基或C(O)O低级烷基,茚满-1-基或茚满-2-基取代, 任选被低级烷基取代; 苊-1-基; 双环-3-氨基-9-基,八氢 - 茚-2-基; 2,3-二氢-1H-phenalen -1-基; 2,3,3a,4,5,6-六氢-1H-吩酚-1-基,十氢 - 薁-2-基; bicycloÄ6.2.0Üdec-9-基; 十氢萘-1-基,十氢萘-2-基; 四氢 - 萘-1-基,四氢 - 萘-2-基或2-氧代-1,2-二苯基 - 乙基; R 2是= O或氢,R 3是氢,异吲哚基-1,3-二酮,低级烷氧基,低级烷基,氨基,苄氧基,-CH 2 OR 5或-CH 2 N(R 5)2 ; R 4是氢或-CH 2 OR 5; R 5是氢或低级烷基; 芳基和环烷基是任选被低级烷基,卤素或烷氧基取代的环己基或苯基; 外消旋混合物及其相应的对映体及其药学上可接受的酸加成盐。 本发明的化合物是神经元FQ(OFQ)受体的激动剂和/或拮抗剂,因此可用于治疗与该受体有关的疾病。
摘要:
The present invention relates to compounds of the general formula wherein
R 1 is C 6 - 10 -cycloalkyl, optionally substituted by lower alkyl or -C(O)O-lower alkyl; decahydro-naphthalen-1-yl; decahydro-naphthalen-2-yl; indan-1-yl or indan-2-yl, optionally substituted by lower alkyl; decahydro-azulen-2-yl; bicyclo[6.2.0]dec-9-yl; acenaphthen-1-yl; 2,3-dihydro-1H-phenalen-1-yl; 2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl or octahydro-inden-2-yl; R 2 is hydrogen; lower alkyl; =O or phenyl, optionally substituted by lower alkyl, halogen or alkoxy; Ⓐ is cyclohexyl or phenyl, optionally substituted by lower alkyl, halogen or alkoxy; X is -CH(OH)-; -C(O)-; -CHR 3 -; -CR 3 =; -O-; -S-; -CH(COOR 4 )- or - C(COOR 4 )=; Y is -CH 2 -; -CH=; -CH(COOR 4 )-, -C(COOR 4 )=; or -C(CN)-; R 3 is hydrogen or lower alkoxy; R 4 is lower alkyl, cycloalkyl, phenyl, or benzyl and either a or b is optionally an additional bond, and to pharmaceutically acceptable acid addition salts thereof.
The compounds are agonists and/or antagonists of the orphanin FQ (QFQ) receptor and therefore useful in the treatment of diseases, related to this receptor.